Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
Adv Mater. 2020 Dec;32(51):e2002440. doi: 10.1002/adma.202002440. Epub 2020 Oct 5.
Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development.
外泌体是一类直径约 100nm 的细胞外囊泡,大多数细胞都会分泌外泌体,其中包含反映其细胞来源的各种生物活性分子,并介导细胞间的通讯。对这些外泌体在肿瘤发病机制中的特征的研究,促使人们开发出了使用外泌体进行癌症治疗的治疗和诊断方法。外泌体在传递治疗剂方面具有许多优势,如小干扰 RNA、microRNA、膜相关蛋白和化疗药物化合物;因此,它们被认为是癌症治疗的首选递送工具。由于外泌体还为免疫调节因子的有效功能提供了最佳的微环境,因此携带生物活性分子的外泌体已被生物工程化为癌症免疫疗法,可以有效激活癌症免疫周期的各个阶段,成功引发针对癌症的特异性免疫。本文综述了外泌体在癌症治疗方面的优势,以及为实现其成功的临床开发而必须克服的挑战。